Results 151 to 160 of about 66,770 (302)

Clinical characteristics and treatment outcomes of patients with IgG4-positive ocular adnexal marginal zone B-cell lymphoma

open access: yesIndian Journal of Ophthalmology
Purpose: To explore the clinicopathological characteristics of immunoglobulin G4 (IgG4)-positive ocular adnexal marginal zone B-cell lymphoma (OAML) and associated patient treatment outcomes.
Yu Yang   +3 more
doaj   +1 more source

Structural features of human immunoglobulin G that determine isotype-specific differences in complement activation. [PDF]

open access: yes, 1993
Although very similar in sequence, the four subclasses of human immunoglobulin G (IgG) differ markedly in their ability to activate complement. Glu318-Lys320-Lys322 has been identified as a key binding motif for the first component of complement, C1q ...
Morrison, SL, Smith, RI, Tao, MH
core  

Circulating Type 2 Memory B Cell Frequency Is a Biomarker for Allergen Immunotherapy Efficacy in Patients With Allergic Rhinitis

open access: yes
Allergy, EarlyView.
Yue Ma   +10 more
wiley   +1 more source

Determinants of Immunoglobulin‐G N‐Glycan Patterns in the Aging General Population

open access: yesAllergy, EarlyView.
The effect of demographic and lifestyle factors on IgG N‐glycosylation, which determines IgG's inflammatory response, remains poorly characterized. Aging, higher BMI, female sex, smoking, and heavy alcohol consumption are determinants of IgG N‐glycome patterns, which are indicative of inflammation. Women exhibit a distinct change in IgG N‐glycosylation
Samantha Leonard   +10 more
wiley   +1 more source

IgE Antibody Function and Mast Cell Activation to Egg in Children Undergoing Baked and Loosely Cooked Egg Challenges

open access: yesAllergy, EarlyView.
MAT is dependent on the presence of allergen‐specific IgE and can provide false‐negative results in allergic patients with low allergen‐specific IgE levels. MAT and BAT are moderately correlated. MAT can be used as a surrogate of BAT, when fresh blood is not available or in the case of patients with non‐releaser basophils.
Vikki Houghton   +6 more
wiley   +1 more source

A Personalised Vaccination Program Based on Immune Reconstitution in Paediatric Cancer Survivors

open access: yesActa Paediatrica, EarlyView.
ABSTRACT Aims Paediatric cancer survivors often experience treatment‐induced immunosuppression, requiring post‐treatment revaccination. However, immune recovery timelines vary, and current revaccination guidelines, largely based on data of varied quality derived from studies on acute‐lymphoblastic‐leukaemia (ALL), may not be applicable across all ...
Menucha Jurkowicz   +17 more
wiley   +1 more source

Checkpoint inhibitors, obinutuzumab plus PET‐adapted ultra‐low dose nodal radiotherapy yield high efficacy in treatment‐naïve follicular lymphoma: Results from the phase II ‘FLUORO’ study

open access: yesBritish Journal of Haematology, EarlyView.
Summary Follicular lymphoma (FL) first‐line chemoimmunotherapy yields high efficacy but serious toxicity in 65% of patients. In high tumour burden treatment‐naïve FL, we aimed to exploit known immunostimulatory and cytotoxic properties of combination checkpoint inhibition (atezolizumab) and obinutuzumab (6 cycles) with positron emission tomography (PET)
Arina Martynchyk   +15 more
wiley   +1 more source

Deciphering the full spectrum of Castleman diseases based on a cohort of 700 patients in a western country

open access: yesBritish Journal of Haematology, EarlyView.
The spectrum of Castleman diseases has expanded over the past three decades. The phenotype of the diseases varies not only among the three major types but also according to the patient ancestry. Summary Under the Castleman disease (CD) eponym, three distinct diseases sharing common pathological features have been described over time.
Eric Oksenhendler   +4 more
wiley   +1 more source

Algorithms in Allergy: General Allergen Molecule‐Based Algorithm for Allergen‐Specific Immunotherapy

open access: yes
Allergy, EarlyView.
Huey‐Jy Huang   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy